<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene A67V;H69del;V70del;T95I;G142D;V143del;Y144del;Y145del;N211del;L212I;G339D;S371F;S373P;S375F;D405N;K417N;N440K;G446S;S477N;T478K;E484A;Q493R;Q498R;N501Y;Y505H;D614G;H655Y;N679K;P681H;N764K;D796Y;Q954H;N969K literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.A67V;H69_V70del;T95I;G142D;V143_Y144_Y145del;N211del;L212I;G339D;S371F;S373P;S375F;D405N;K417N;N440K;G446S;S477N;T478K;E484A;Q493R;Q498R;N501Y;Y505H;D614G;H655Y;N679K;P681H;N764K;D796Y;Q954H;N969K</span> literature reference collection</h1>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 6.2-fold lower (95% CI: 11.8x-14.3x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.<br/> (<a href="https://doi.org/10.1101/2022.06.05.494889" class="lit_link">Kurhade et al. (2022)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccinee_plasma_binding">Vaccinee plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In 22 Pfizer/BNT162b2-vaccinated sera (ages 26-74, median 65) collected 1 month after dose 3,  BA.3 (from South Africa/NICD-N22404/2021) were 4.2x-fold lower (95% CI: 0.15x-0.20x) than against  US-WA1/2020 using an infectious cDNA clone of mNG USA-WA1/2020.<br/> (<a href="https://doi.org/10.1101/2022.06.05.494889" class="lit_link">Kurhade et al. (2022)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
